1 / 8

Michael A. Mussallem

Michael A. Mussallem . Chairman and CEO Edwards Lifesciences Leading the fight against advanced cardiovascular disease. Edwards History. Founded by Miles “Lowell” Edwards in 1958 Inventor and visionary, held 60+ patents

nicodemus
Télécharger la présentation

Michael A. Mussallem

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Michael A. Mussallem Chairman and CEO Edwards Lifesciences Leading the fight against advancedcardiovascular disease

  2. Edwards History • Founded by Miles “Lowell” Edwards in 1958 • Inventor and visionary, held 60+ patents • Partnered with physicians to introduce breakthrough medical devices to the world • Changes in ownership • 1958 Edwards Laboratories • 1968 American Hospital Supply Corp. • 1984 Baxter International Inc. • 2000 Edwards Lifesciences (NYSE:EW)

  3. Edwards Leads Growth Industry • A leader in treating advanced cardiovascular disease • Cardiovascular disease is progressive; leading killer and health expense • 2007 Sales: $1.091 billion • 2008 projected sales ~ $1.2+ billion • Broad global presence • Products sold in ~100 countries • 5,600+ employees World’s Leading Killers 2007 Sales By Region

  4. Edwards’ Global Operations St.-Prex, Switzerland Horw, Switzerland Mississauga, Canada Tokyo, Japan Salt Lake City Irvine Haina, Dominican Republic Mumbai, India Añasco, Puerto Rico Singapore Sao Paulo, Brazil 40+ offices in 35 countries

  5. Edwards’ Robust Core Businesses 2007 Global Heart Valve Sales* • 90% of sales from products with #1 global positions • Leader in heart valve therapy • Leader in hemodynamic monitoring • High barriers to entry • Strong brand recognition • Trusted partner with leading clinicians • Strong base from which innovation can flourish $1.1 billion 2007 Global Hemodynamic Monitoring Sales* $435 million *Estimated

  6. A patient focus Targeted populations are large and growing Cardiovascular disease remains the leading cause of death and largest healthcare expense Sizable growth opportunities Targeting transformational technologies in Structural Heart Disease and Critical Care Medicine A product leadership strategy Clinical superiority remains our primary basis of differentiation and competitive advantage Edwards’ Global Strategy

  7. Business practice scrutiny Reimbursement pressure Regulatory timelines Global and local competitors Price transparency Global Challenges/Opportunities

  8. Helping Patients is Our Life’s Work, and

More Related